[go: up one dir, main page]

EP4676462A1 - Thérapie contre le cancer de la vessie - Google Patents

Thérapie contre le cancer de la vessie

Info

Publication number
EP4676462A1
EP4676462A1 EP24708504.6A EP24708504A EP4676462A1 EP 4676462 A1 EP4676462 A1 EP 4676462A1 EP 24708504 A EP24708504 A EP 24708504A EP 4676462 A1 EP4676462 A1 EP 4676462A1
Authority
EP
European Patent Office
Prior art keywords
composition
therapy
bladder cancer
bladder
hal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24708504.6A
Other languages
German (de)
English (en)
Inventor
Gry Stensrud
Aslak Godal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Publication of EP4676462A1 publication Critical patent/EP4676462A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le traitement du cancer de la vessie. En particulier, l'invention concerne une composition comprenant un ester d'hexyle 5-ALA (HAL), ou un sel pharmaceutiquement acceptable de celui-ci, destinée à être utilisée dans une méthode de traitement du cancer de la vessie, ladite méthode comprenant l'instillation de ladite composition dans la vessie d'un patient, et ladite méthode n'étant pas une méthode de thérapie photodynamique.
EP24708504.6A 2023-03-07 2024-03-06 Thérapie contre le cancer de la vessie Pending EP4676462A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23160601 2023-03-07
PCT/EP2024/055897 WO2024184417A1 (fr) 2023-03-07 2024-03-06 Thérapie contre le cancer de la vessie

Publications (1)

Publication Number Publication Date
EP4676462A1 true EP4676462A1 (fr) 2026-01-14

Family

ID=85510919

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24708504.6A Pending EP4676462A1 (fr) 2023-03-07 2024-03-06 Thérapie contre le cancer de la vessie

Country Status (6)

Country Link
EP (1) EP4676462A1 (fr)
KR (1) KR20250154511A (fr)
CN (1) CN120957714A (fr)
AU (1) AU2024231397A1 (fr)
IL (1) IL323158A (fr)
WO (1) WO2024184417A1 (fr)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7530461B2 (en) 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
PT820432E (pt) 1995-03-10 2001-09-28 Photocure Asa Esteres do acido 5-aminolevulinico como agentes fotossensibilizadores em fotoquimioterapia
EP2206517B1 (fr) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Compositions immunostimulantes contenant un anticorps anti-PD-L1
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
CA2691357C (fr) 2007-06-18 2014-09-23 N.V. Organon Anticorps diriges contre le recepteur humain de mort programmee pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP4331604B9 (fr) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
US9012502B2 (en) 2010-09-14 2015-04-21 Sbi Pharmaceuticals Co., Ltd. Cancer heat therapy-enhancing agent
KR20190133790A (ko) 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
MX363872B (es) 2012-05-31 2019-04-05 Genentech Inc Anticuerpos anti-pd-l1 y antagonistas de vegf y su uso en el tratamiento del cáncer.
BR112015002390B1 (pt) 2012-08-03 2020-03-24 Photocure Asa Derivados do ácido 5-aminolevulínico (5-ala), sua composição e seu uso como agentes fotossensibilizantes
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
BR112018011965A2 (pt) 2015-12-17 2018-12-04 Photocure Asa método de terapia fotodinâmica (pdt) para câncer de bexiga
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use

Also Published As

Publication number Publication date
KR20250154511A (ko) 2025-10-28
CN120957714A (zh) 2025-11-14
WO2024184417A1 (fr) 2024-09-12
AU2024231397A1 (en) 2025-09-25
IL323158A (en) 2025-11-01

Similar Documents

Publication Publication Date Title
US11980772B2 (en) Method of photodynamic therapy (PDT) for bladder cancer
US11066478B2 (en) Intravesical therapy for bladder cancer
KR102787188B1 (ko) 방광암에 대한 신보조 요법
CA2729369C (fr) Internalisation photochimique d'inhibiteurs de kinase
US7772255B2 (en) Method of treating tumors with azaxanthones
WO2024184417A1 (fr) Thérapie contre le cancer de la vessie
CA2519289A1 (fr) Polytherapie contre des tumeurs comprenant l'administration de nemorubicine combinee a une radiotherapie
RU2783177C2 (ru) Неоадъювантная терапия для рака мочевого пузыря
RU2779543C2 (ru) Внутрипузырная терапия для рака мочевого пузыря
HK1262650A1 (en) Method of photodynamic therapy (pdt) for bladder cancer
HK1262650B (en) Method of photodynamic therapy (pdt) for bladder cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR